Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Zarka, Jabra http://orcid.org/0000-0001-8668-6741
Sasaki, Koji
Qiao, Wei
Pak, Daewoo
Ning, Jing
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
Haddad, Fadi
Tang, Zhenya http://orcid.org/0000-0002-8079-9945
Patel, Keyur P. http://orcid.org/0000-0001-5081-2427
Cuglievan, Branko
Daver, Naval http://orcid.org/0000-0001-7103-373X
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Jabbour, Elias http://orcid.org/0000-0003-4465-6119
Kadia, Tapan http://orcid.org/0000-0002-9892-9832
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
Kantarjian, Hagop M. http://orcid.org/0000-0002-1908-3307
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Article History
Received: 2 July 2021
Revised: 3 September 2021
Accepted: 8 September 2021
First Online: 29 September 2021
Competing interests
: G.C.I. received research funding from Celgene, Kura Oncology, Syndax, and Novartis, and received consultancy fees from Novartis and Kura Oncology. K.S. received research funding from Novartis and consulting or advisory fees from Otsuka, Novartis, Pfizer, and Takeda. N.J.S. has served as a consultant for Takeda Oncology, AstraZeneca, and Jazz Pharmaceuticals, reports receiving research grants from Takeda Oncology and Astellas Pharma Inc. and has received honoraria from Amgen. C.D.D. received research funding from Abbvie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi-Sankyo, Forma, ImmuneOnc, Loxo, and received consultancy or advisory board fees from AbbVie, Agios, Novartis, Aprea, Celgene/BMS, ImmuneOnc, Notable Laboratories, and Takeda. E.J. received research funding from Abbvie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Pfizer, and Takeda and received advisory board fees from Genetech. N.D. has received research funding from Daiichi-Sankyo, Bristol Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck Labs, and Agios. T.K. has received research funding from Bristol Myers Squibb, Celgene, Sanofi, Amgen, BiolineRx, Incyte, Genentech/AbbVie, Pfizer, Jazz Pharmaceuticals, AstraZeneca, Astellas Pharma, Ascentage Pharma, Genfleet, Cyclacel and received consulting or advisory board fees from Novartis, Jazz Pharmaceuticals, Pfizer, AbbVie/Genentech, and Agios. G.B. has received research funding from Incyte, GlaxoSmithKline, Cyclacel, BiolineRx, MedImmune, Lilly, Oncoceutics, Ryvu Therapeutics, Janssen Scientific Affairs, Bristol Myers Squibb, AbbVie, Novartis, AstraZeneca, Mundipharma Research, PTC Therapeutics, BioTheryX, XBiotech, Arvinas, Astex Pharmaceuticals, TCR2 Therapeutics, Nkarta, Treadwell Therapeutics, Cellestia Biotech, and consulting or advisory board fees from Argenx, PTC Therapeutics, BiolineRx, BioTheryX, Nkarta, Treadwell Therapeutics, Novartis, Catamaran Bio, and Takeda. G.G.-M. received research funding from Celgene, Astex Pharmaceuticals, Amphivena, Helsinn Therapeutics, Novartis, AbbVie, Bristol Myers Squibb, Onconova Therapeutics, H3 Biomedicine, Merck and consulting or advisory board fees from Celgene, Astex Pharmaceuticals, Acceleron Pharma, Helssin, and AbbVie. M.K. has received research funding from AbbVie, Genentech, Roche, Lilly, Cellectis, Calithera Biosciences, Ablynx, Agios, Ascentage Pharma, AstraZeneca, Sanofi and received honoraria or advisory board fees from AbbVie, Genentech, Roche, Amgen, Stemline Therapeutics, KisoJi Biotechnology, Stemline Therapeutics, Forty Seven, and Janssen. M.A. received research funding from Daiichi-Sankyo, and consultancy honoraria from Syndax, Jazz, Celgene, Amgen, AstraZeneca, Dimensions Capital, and equity ownership from Reata, Aptose, Europics, Senti Bio, Chimerix, and Oncolyze. H.M.K. received research funding from Ariad, Astex, Bristol Myers Squibb, Cyclacel, Daiichi-Sankyo, Pfizer, Immunogen, Jazz, Novartis and honoraria from Pfizer, Immunogen, Actinium, and Takeda. F.R. received research funding from Amgen, Bristol Myers Squibb, Sunesis Pharmaceuticals, Pfizer, Xenecor, Macrogenetics, Taiho, Astex, Abbvie and honoraria for consulting or advisory role from Jazz, Amgen, Celgene, Astellas, Syros, Taiho, Novartis, AstraZeneca, Agios, and Bristol Myers Squibb.